Services and products for clinical and preclinical research
Stem cell and drug discovery scientists around the world use our solutions to translate their research into therapies.
Service Areas
Blog
The Critical Role of Central Laboratory Services in Regulatory Compliance and Data Integrity
Explore the critical role of Central Laboratory Services in ensuring data integrity and regulatory compliance in drug development. Learn how CLS supports reliable, reproducible, and auditable data.
27 January 2026
Modeling Fibrosis Progression Ex Vivo: Opportunities for Anti-Fibrotic Drug Screening
Explore the benefits of ex vivo human tissue models for fibrosis research and anti-fibrotic drug screening, offering a more accurate alternative to conventional preclinical methods.
15 January 2026
OpenCRISPR-1: The First AI-Designed CRISPR Editor for High-Precision Gene & Cell Therapy
Discover OpenCRISPR-1 — the first fully AI-designed CRISPR–Cas editor. Built by generative large language model, it enables high-efficiency, high-specificity genome and base editing in human cells. Ideal for cell therapy, stem-cell research, and advanced gene-editing workflows.
16 December 2025
Enhancing Experimental Precision with the Alvetex® Advanced Culture System
Discover how Alvetex® Advanced enhances experimental precision with its flexible and functional 3D culture system for creating biologically accurate human skin models.
04 December 2025
Upcoming Events
Conferences we will be attending, and webinars hosted by us
Corporate News
28 January 2026
07 November 2025
REPROCELL USA Receives Funding from the Maryland Stem Cell Research Fund (MSCRF)
22 October 2025
Investor Relations News
- Jan 27, 2026
-
Notice Regarding the Launch of "StemEdit," a Clinical-Grade Gene Editing Service
Jan 27, 2026 - Jan 26, 2026









